BioNTech SE : Strong Q4 2022 figures – 2023 guidance disappointing
>FY22 Q4 figures topped beat our expectations and those of the market - Q4 revenues was € 4.278m, beating our estimate of € 3,850m and the consensus forecast of € 3,950m. As a result of the development of the coronavirus pandemic BioNTech’s top line declined y-o-y by 23%. EBIT was at € 3.293m vs our estimates of € 2,743m and the consensus forecast of € 2,817m. The EBIT margin declined y-o-y by nearly 800bp to 77%. BioNTech is guiding for 2023 Covid-19 vac...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.